arrow
R

Robert Mróz

university teaching hospital
H指数:21
被引数:5,014

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study

Rilzabrutinib用于症状未控制的轻至重度哮喘患者的治疗:一项双盲、安慰剂对照的2期研究

2026-04-020
PRE
Translating tumor epigenetic subtyping into methylome network-based prognostic models in early-stage NSCLC: results from the prospective MOBIT study

将肿瘤表观遗传亚型分类转化为基于甲基化组网络的早期NSCLC预后模型:来自前瞻性MOBIT研究的结果

2026-03-120
OAAI
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study☆

度伐鲁单抗在不可切除的III期非小细胞肺癌且不符合化疗指征的患者放疗后的应用:DUART II期非随机对照研究☆

2025-08-200
PREAI
Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial

循环肿瘤DNA (ctDNA) 动态和治疗效果:来自II期DUART试验中不可切除III期NSCLC化疗不适宜患者(pts)的数据

2024-09-012
PRE
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
LANCET
IF88.5
2019-11-011.4K
PREAI
Asthma-COPD Overlap-A Discordance Between Patient Populations Defined by Different Diagnostic Criteria
2019-09-0123
PREAI